224P - Clinical implication and usefulness of serum heparin-binding EGF-like growth factor as a potential serological biomarker for gastric cancer

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Gastric Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Jong-Baeck Lim
Citation Annals of Oncology (2014) 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
Authors J. Lim1, H.W. Chung2
  • 1Department Of Laboratory Medicine, Yonsei University College of Medicine, 120-752 - Seoul/KR
  • 2Department Of Internal Medicine, Division Of Gastroenterology, International ST. Mary’s Hospital, 404-834 - Incheon/KR



Heparin-binding EGF-like growth factor (HB-EGF), a member of the EGF family, is overexpressed in human gastric cancer (GC) and considered to play an important role in carcinogenesis of GC as soluble form. This study evaluated the clinical implication of serum HB-EGF in patients with GC and validated its potential as a biomarker for GC.


Serum HB-EGF level was measured by the commercially available human HB-EGF ELISA Kit and compared among 60 normal/gastritis patients (control group), 30 patients with intestinal metaplasia (IM)/dysplasia (high-risk group), 37 early GC (EGC) patients (EGC group), and 30 advanced GC (AGC) patients (AGC group) along the gastric carcinogenesis through one-way ANOVA test. Correlations of serum HB-EGF with clinicopathological parameters of GC were evaluated by Spearman's correlation. To evaluate the diagnostic potential of serum HB-EGF for GC, receiver operating characteristic (ROC) curve was generated and logistic regression analysis was performed.


Serum HB-EGF levels were increased along the GC carcinogenesis (gastritis-dysplasia-EGC-AGC sequence). Serum HB-EGF levels were significantly higher in AGC groups (314.4 ± 127.5) than EGC (165.3 ± 123.2), high-risk (98.7 ± 67.3) and normal control (94.7 ± 83.6) groups (each p < 0.001; post-hoc Bonferroni, ANOVA), respectively. Serum HB-EGF levels in EGC groups were also significantly higher than high-risk (p = 0.049) and normal (p = 0.006) groups, respectively. Clinicopathologically, serum HB-EGF levels were closely correlated with primary GC size (ɣs = 0.237, p = 0.048; Spearman's correlation), depth of invasion (T-stage, ɣs = 0.669, p <0.001), lymph node metastasis (N-stage, ɣs = 0.407, p = 0.001), and distant metastasis (M-stage, ɣs = 0.261, p = 0.030). ROC curve and logistic regression analysis demonstrated a remarkable diagnostic accuracy of serum HB-EGF (76.1% sensitivity and 76.5% specificity at cut-off point, 0.38; logistic regression) compared with those of CEA (62.1% and 51.8% at cut-off point, 0.38, respectively).


Serum HB-EGF exhibited a noticeable diagnostic accuracy to predict GC. Also, serum HB-EGF levels were closely correlated with primary tumor size, depth of invasion, lymph node metastasis, and distant metastasis. Collectively, Serum HB-EGF is a potential serologic biomarker candidate for GC superior to CEA.


All authors have declared no conflicts of interest.